secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001140361-24-025329
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Q1 net loss $7.1M ($0.29/sh); cash $47.2M; RYZUMVI launch yields first royalty
--------------------------------------------------------------------------------

- Net loss of $7.1M ($0.29 per share) vs $5.8M ($0.28) in Q1 2023.
- Cash and equivalents $47.2M; management expects funding into mid-2025.
- License revenue flat at $1.7M; first RYZUMVI royalty of $3,000 recognized.
- Partner Viatris launched RYZUMVI in April 2024; LYNX-2 Phase 3 trial enrolled first subject.
- FDA SPA dialogue for APX3330 Phase 2/3 DR trial ongoing; timing of agreement TBD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124025329/0001140361-24-025329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124025329/ef20028807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-025329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer